Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes

Molecular Therapy

Volumn 23, Issue 12, 2015, Pages 1888-1898

  Moody, Paul R ^a   Sayers, Edward J ^a   Magnusson, Johannes P ^b   Alexander, Cameron ^b   Borri, Paola ^a   Watson, Peter ^a   Jones, Arwyn T ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; STREPTAVIDIN; TRANSFERRIN; TRASTUZUMAB; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; LIGAND; PRODRUG;

ARTICLE; BREAST CANCER CELL LINE; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; INTERNALIZATION; LYSOSOME; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; CELL MEMBRANE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; GENE TARGETING; GENETICS; HELA CELL LINE; METABOLISM; PROCEDURES; PROTEIN TRANSPORT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FEMALE; GENE TARGETING; HELA CELLS; HUMANS; IMMUNOCONJUGATES; LIGANDS; LYSOSOMES; PRODRUGS; PROTEIN TRANSPORT; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84952637932     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.178     Document Type: Article

References (69)

1. Bien-Ly, N, Yu, YJ, Bumbaca, D, Elstrott, J, Boswell, CA, Zhang, Y et al. (2014). Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med 211: 233-244.
2. Niewoehner, J, Bohrmann, B, Collin, L, Urich, E, Sade, H, Maier, P et al. (2014). Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81: 49-60.
3. Wiley, DT, Webster, P, Gale, A and Davis, ME (2013). Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci USA 110: 8662-8667.
4. Casi, G and Neri, D (2012). Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release 161: 422-428.
5. Bander, NH (2013). Antibody-drug conjugate target selection: critical factors. Methods Mol Biol 1045: 29-40.
6. Dubowchik, GM, Firestone, RA, Padilla, L, Willner, D, Hofstead, SJ, Mosure, K et al. (2002). Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 13: 855-869.
7. Castañeda, L, Maruani, A, Schumacher, FF, Miranda, E, Chudasama, V, Chester, KA et al. (2013). Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation. Chem Commun (Camb) 49: 8187-8189.
8. Oflazoglu, E, Stone, IJ, Gordon, K, Wood, CG, Repasky, EA, Grewal, IS et al. (2008). Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 14: 6171-6180.
9. Maruani, A, Smith, ME, Miranda, E, Chester, KA, Chudasama, V and Caddick, S (2015). A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nat Commun 6: 6645.
10. Breij, EC, de Goeij, BE, Verploegen, S, Schuurhuis, DH, Amirkhosravi, A, Francis, J et al. (2014). An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 74: 1214-1226.
11. Ornes, S (2013). Antibody-drug conjugates. Proc Natl Acad Sci USA 110: 13695-13695.
12. Parton, RG, Schrotz, P, Bucci, C and Gruenberg, J (1992). Plasticity of early endosomes. J Cell Sci 103: 335-348.
13. St Pierre, CA, Leonard, D, Corvera, S, Kurt-Jones, EA and Finberg, RW (2011). Antibodies to cell surface proteins redirect intracellular trafficking pathways. Exp Mol Pathol 91: 723-732.
14. Wang, Q, Villeneuve, G and Wang, Z (2005). Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation. EMBO Rep 6: 942-948.
15. Boersma, YL, Chao, G, Steiner, D, Wittrup, KD and Plückthun, A (2011). Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem 286: 41273-41285.
16. Lindstrom, J and Einarson, B (1979). Antigenic modulation and receptor loss in experimental autoimmune myasthenia gravis. Muscle Nerve 2: 173-179.
17. Lee, CW, Zhang, H, Geng, L and Peng, HB (2014). Crosslinking-induced endocytosis of acetylcholine receptors by quantum dots. PLoS One 9: e90187.
18. Weflen, AW, Baier, N, Tang, QJ, Van den Hof, M, Blumberg, RS, Lencer, WI et al. (2013). Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol Biol Cell 24: 2398-2405.
19. Wu, K, Liu, J, Johnson, RN, Yang, J and Kopecek, J (2010). Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface. Angew Chem Int Ed Engl 49: 1451-1455.
20. Rappoport, JZ and Simon, SM (2003). Real-time analysis of clathrin-mediated endocytosis during cell migration. J Cell Sci 116: 847-855.
21. Collins, BM, McCoy, AJ, Kent, HM, Evans, PR and Owen, DJ (2002). Molecular architecture and functional model of the endocytic AP2 complex. Cell 109: 523-535.
22. Maxfield, FR and McGraw, TE (2004). Endocytic recycling. Nat Rev Mol Cell Biol 5: 121-132.
23. Qian, ZM, Li, H, Sun, H and Ho, K (2002). Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54: 561-587.
24. Daniels, TR, Bernabeu, E, Rodríguez, JA, Patel, S, Kozman, M, Chiappetta, DA et al. (2012). The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 1820: 291-317.
25. Liu, AP, Aguet, F, Danuser, G and Schmid, SL (2010). Local clustering of transferrin receptors promotes clathrin-coated pit initiation. J Cell Biol 191: 1381-1393.
26. Weissman, AM, Klausner, RD, Rao, K and Harford, JB (1986). Exposure of K562 cells to anti-receptor monoclonal antibody OKT9 results in rapid redistribution and enhanced degradation of the transferrin receptor. J Cell Biol 102: 951-958.
27. Rock, KL and Goldberg, AL (1999). Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17: 739-779.
28. Radhakrishna, H and Donaldson, JG (1997). ADP-ribosylation factor 6 regulates a novel plasma membrane recycling pathway. J Cell Biol 139: 49-61.
29. Naslavsky, N, Weigert, R and Donaldson, JG (2003). Convergence of nonclathrin-and clathrin-derived endosomes involves Arf6 inactivation and changes in phosphoinositides. Mol Biol Cell 14: 417-431.
30. Naslavsky, N, Weigert, R and Donaldson, JG (2004). Characterization of a nonclathrin endocytic pathway: membrane cargo and lipid requirements. Mol Biol Cell 15: 3542-3552.
31. Hein, Z, Uchtenhagen, H, Abualrous, ET, Saini, SK, Janßen, L, Van Hateren, A et al. (2014). Peptide-independent stabilization of MHC class I molecules breaches cellular quality control. J Cell Sci 127: 2885-2897.
32. Matko, J, Bushkin, Y, Wei, T and Edidin, M (1994). Clustering of class I HLA molecules on the surfaces of activated and transformed human cells. J Immunol 152: 3353-3360.
33. Mahmutefendi, H, Blagojevi, G, Tomaš, MI, Kui, N and Luin, P (2011). Segregation of open major histocompatibility class I conformers at the plasma membrane and during endosomal trafficking reveals conformation-based sorting in the endosomal system. Int J Biochem Cell Biol 43: 504-515.
34. Rubio, G, Férez, X, Sánchez-Campillo, M, Gálvez, J, Martí, S, Verdú, R et al. (2004). Cross-linking of MHC class I molecules on human NK cells inhibits NK cell function, segregates MHC I from the NK cell synapse, and induces intracellular phosphotyrosines. J Leukoc Biol 76: 116-124.
35. Xu, S, Liu, X, Bao, Y, Zhu, X, Han, C, Zhang, P et al. (2012). Constitutive MHC class I molecules negatively regulate TLR-triggered inflammatory responses via the Fps-SHP-2 pathway. Nat Immunol 13: 551-559.
36. Reed, EF (2003). Signal transduction via MHC class I molecules in endothelial and smooth muscle cells. Crit Rev Immunol 23: 109-128.
37. Lee, H, Brott, BK, Kirkby, LA, Adelson, JD, Cheng, S, Feller, MB et al. (2014). Synapse elimination and learning rules co-regulated by MHC class I H2-Db. Nature 509: 195-200.
38. Austin, CD, De Mazière, AM, Pisacane, PI, van Dijk, SM, Eigenbrot, C, Sliwkowski, MX et al. (2004). Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15: 5268-5282.
39. Barok, M, Joensuu, H and Isola, J (2014). Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 16: 209.
40. Holmes, WE, Sliwkowski, MX, Akita, RW, Henzel, WJ, Lee, J, Park, JW et al. (1992). Identification of heregulin, a specific activator of p185erbB2. Science 256: 1205-1210.
41. Wolff, AC, Hammond, ME, Schwartz, JN, Hagerty, KL, Allred, DC, Cote, RJ et al.; American Society of Clinical Oncology/College of American Pathologists. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43.
42. Bertelsen, V and Stang, E (2014). The mysterious ways of ErbB2/HER2 Trafficking. Membranes (Basel) 4: 424-446.
43. Gennari, R, Menard, S, Fagnoni, F, Ponchio, L, Scelsi, M, Tagliabue, E et al. (2004). Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650-5655.
44. Valabrega, G, Montemurro, F and Aglietta, M (2007). Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18: 977-984.
45. Zhu, W, Okollie, B and Artemov, D (2007). Controlled internalization of Her-2/neu receptors by cross-linking for targeted delivery. Cancer Biol Ther 6: 1960-1966.
46. Friedman, LM, Rinon, A, Schechter, B, Lyass, L, Lavi, S, Bacus, SS et al. (2005). Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 102: 1915-1920.
47. Ben-Kasus, T, Schechter, B, Lavi, S, Yarden, Y and Sela, M (2009). Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci USA 106: 3294-3299.
48. Maron, R, Schechter, B, Mancini, M, Mahlknecht, G, Yarden, Y and Sela, M (2013). Inhibition of pancreatic carcinoma by homo-and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci USA 110: 15389-15394.
49. Mahlknecht, G, Maron, R, Mancini, M, Schechter, B, Sela, M and Yarden, Y (2013). Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci USA 110: 8170-8175.
50. Hapuarachchige, S, Zhu, W, Kato, Y and Artemov, D (2014). Bioorthogonal, twocomponent delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics. Biomaterials 35: 2346-2354.
51. Roberts, RL, Fine, RE and Sandra, A (1993). Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J Cell Sci 104: 521-532.
52. Gole, A and Murphy, CJ (2005). Biotin-streptavidin-induced aggregation of gold nanorods: tuning rod-rod orientation. Langmuir 21: 10756-10762.
53. Chen, LQ, Xiao, SJ, Hu, PP, Peng, L, Ma, J, Luo, LF et al. (2012). Aptamer-mediated nanoparticle-based protein labeling platform for intracellular imaging and tracking endocytosis dynamics. Anal Chem 84: 3099-3110.
54. Humphries, WH 4th, Szymanski, CJ and Payne, CK (2011). Endo-lysosomal vesicles positive for Rab7 and LAMP1 are terminal vesicles for the transport of dextran. PLoS One 6: e26626.
55. Motley, A, Bright, NA, Seaman, MN and Robinson, MS (2003). Clathrin-mediated endocytosis in AP-2-depleted cells. J Cell Biol 162: 909-918.
56. Singh, RD, Puri, V, Valiyaveettil, JT, Marks, DL, Bittman, R and Pagano, RE (2003). Selective caveolin-1-dependent endocytosis of glycosphingolipids. Mol Biol Cell 14: 3254-3265.
57. Cuello, M, Ettenberg, SA, Clark, AS, Keane, MM, Posner, RH, Nau, MM et al. (2001). Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61: 4892-4900.
58. zum Büschenfelde, CM, Hermann, C, Schmidt, B, Peschel, C and Bernhard, H (2002). Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 62: 2244-2247.
59. Scaltriti, M, Verma, C, Guzman, M, Jimenez, J, Parra, JL, Pedersen, K et al. (2009). Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28: 803-814.
60. Wimmer-Kleikamp, SH, Janes, PW, Squire, A, Bastiaens, PI and Lackmann, M (2004). Recruitment of Eph receptors into signaling clusters does not require ephrin contact. J Cell Biol 164: 661-666.
61. Janes, PW, Griesshaber, B, Atapattu, L, Nievergall, E, Hii, LL, Mensinga, A et al. (2011). Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors. J Cell Biol 195: 1033-1045.
62. Lindstrom, JM (2000). Acetylcholine receptors and myasthenia. Muscle Nerve 23: 453-477.
63. Zhang, B, Koh, YH, Beckstead, RB, Budnik, V, Ganetzky, B and Bellen, HJ (1998). Synaptic vesicle size and number are regulated by a clathrin adaptor protein required for endocytosis. Neuron 21: 1465-1475.
64. Yumura, K, Ui, M, Doi, H, Hamakubo, T, Kodama, T, Tsumoto, K et al. (2013). Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin. Protein Sci 22: 213-221.
65. Barginear, MF, John, V and Budman, DR (2012). Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med 18: 1473-1479.
66. Hughes, JB, Rødland, MS, Hasmann, M, Madshus, IH and Stang, E (2012). Pertuzumab increases 17-AAG-induced degradation of ErbB2, and this effect is further increased by combining pertuzumab with trastuzumab. Pharmaceuticals (Basel) 5: 674-689.
67. Kamaly, N, Xiao, Z, Valencia, PM, Radovic-Moreno, AF and Farokhzad, OC (2012). Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 41: 2971-3010.
68. Bolte, S and Cordelières, FP (2006). A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224: 213-232.
69. Al-Soraj, MH, Watkins, CL, Vercauteren, D, De Smedt, SC, Braeckmans, K and Jones, AT (2010). siRNA versus pharmacological inhibition of endocytic pathways for studying cellular uptake of cell penetrating peptides. J Control Release 148: e86-e87.